Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent obtained~* male or female patients aged 5 to 18 years at time of screening~* of non-childbearing potential, of childbearing potential and willing to use specific barrier methods outlined in the protocol~* confirmed active EE (at Screening or within six weeks prior to Baseline Visit) as defined by esophageal mucosal eosinophils greater than or equal to 24 per high power field (hpf; 400X magnification)~* within the week prior to dosing, patient has one of the following symptoms of moderate (or worse) severity: vomiting, regurgitation (acid taste or feeling material movement upward), abdominal, chest pain/heartburn (burning or pain behind the sternum), or difficulty swallowing~* been on a therapeutic dose of proton pump inhibitors (PPIs; with or without histamine H2 receptor antagonists)for at least four weeks without resolution of symptoms, or by negative pH probe (with or without having failed a course of PPIs)~Exclusion Criteria:~* another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome \[HES\],Churg Strauss vasculitis, eosinophilic gastroenteritis \[EG\], or a parasitic infection)~* history of abnormal gastric or duodenal biopsy or documented gastrointestinal \[GI\] disorders (e.g., celiac disease, Crohn's disease or Helicobacter pylori infection)~* history of the following GI surgeries: fundoplication, gastric surgery or surgery for intestinal atresia~* use of systemic immunosuppressive or immunomodulating agents (anti-immunoglobulin E \[IgE\] monoclinal antibody \[mAb\], methotrexate, cyclosporin, interferon alpha \[α\], or anti tumor necrosis factor \[TNF\] mAb) within six months prior to study entry~* received attenuated live attenuated vaccines (e.g., measles, mumps, rubella \[MMR\], bacillus Calmette-Guerin \[BCG\], varicella, FluMist or polio) within three months prior to study entry~* use of swallowed inhaled corticosteroids for the treatment of EE within one month prior to study entry. Note: Inhaled and nasal corticosteroids for the treatment of asthma and allergies, respectively, are permitted provided that the dose remains the same during the study~* a stricture on endoscopy that prevents passage of the endoscope~* participation in any investigational drug or device study within 30 days prior to study entry~* female subjects who are pregnant or nursing~* concurrent infection or disease that may preclude assessment of EE~* concurrent immunodeficiency (human immunodeficiency \[HIV\], or acquired immunodeficiency syndrome \[AIDS\] or congenital immunodeficiency)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Reslizumab 1 mg/kg (Type: EXPERIMENTAL): reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
- Reslizumab 2 mg/kg (Type: EXPERIMENTAL): reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
- Reslizumab 3 mg/kg (Type: EXPERIMENTAL): reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
- Placebo (Type: PLACEBO_COMPARATOR): saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).